Klobuchar defends her record on regulating medical devices

In this Sunday, Feb. 24, 2019, photo, U.S. Sen. Amy Klobuchar, D-Minn., speaks to voters during a campaign stop at a home in Nashua, N.H. U.S. Sen. and presidential hopeful Klobuchar has built a reputation as an effective champion for consumer safety. She also aggressively advocated for the medical device industry - a big employer in her home state of Minnesota - in ways that complicate her reputation as a consumer defender. Some consumer advocates say her work has helped put patients at risk. (AP Photo/Steven Senne)

MINNEAPOLIS — In her more than two terms as a U.S. senator representing Minnesota, Amy Klobuchar has built a reputation as an effective champion for consumer safety, sponsoring bills that improve swimming pool safety, ban lead in children's products and tackle the nation's opioid crisis.

"Consumers deserve products that have been tested and meet strong health and safety standards," her website declares.

But Klobuchar, who announced two weeks ago she will contend for the 2020 Democratic presidential nomination, has also forcefully advocated for the medical device industry — a huge employer in her home state — in ways that complicate her reputation as a consumer defender.

During her time in the Senate, Klobuchar has advanced proposals championed by the medical device industry that some consumer advocates claim would put patients' safety at risk, a review of her record by The Associated Press and the International Consortium of Investigative Journalists found. Safety and regulatory concerns relating to medical devices have come under scrutiny since the AP, ICIJ and other media partners began publishing a series of investigative stories about the industry in late 2018.

Klobuchar has pushed the federal Food and Drug Administration to approve medical devices faster and called for a greater presence of industry-backed experts at the agency. Not all of her proposals became law, but bills she introduced called for reducing the use of randomized clinical trials for some devices and limiting the amount of information FDA reviewers can ask of companies when evaluating devices. Language in bills she sponsored to streamline device approvals and increase the influence of industry-recommended experts ultimately ended up in landmark legislation signed into law by President Barack Obama.

While many of her Democratic presidential rivals promote ambitious proposals for free health care and college tuition, Klobuchar's work on medical devices is a window into her narrower, often more moderate policy portfolio.

Klobuchar defends her record on regulating medical devices, telling the AP in a statement, "Patient and consumer rights have always been a major focus of mine."

___

This story was produced through a partnership between The Associated Press and the International Consortium of Investigative Journalists.

___

Klobuchar did not make herself available for an interview for this story. Her statement highlights her efforts to speed up approvals of new devices, noting that approvals for many life-saving devices had languished for years.

"The legislation to improve the process was passed as part of a larger package of reforms, signed into law by President Obama, in response to slow-downs and workforce shortages at the FDA," Klobuchar said. "The legislation also included more funding for the FDA to hire medical experts to examine the safety of products that came before them for approval. The final legislation was supported by numerous patient safety groups."

Diana Zuckerman, president of the nonpartisan National Center for Health Research think tank, said that Klobuchar's legislative record has put the demands of the device industry above patient safety. It has also provided political cover that makes it easier for other progressive lawmakers to embrace pro-industry measures, Zuckerman said.

"When a liberal Democrat actively champions a position that harms patients, as Sen. Klobuchar has done on FDA legislation, it helps to persuade other liberal Democrats," Zuckerman said.

Dr. Margaret Hamburg, head of the FDA from May 2009 to April 2015, said Klobuchar worked on streamlining the process, but was also concerned about conflict of interest issues that could put consumers at risk — sponsoring legislation that required both medical device makers and drug companies to disclose payments they make to doctors and researchers.

Hamburg said others in Congress expressed similar concern.

"There was a great deal of concern about making sure that American consumers were getting cutting-edge medical devices as soon or sooner than anyone else in the world, but also concern about ensuring the safety of those products," Hamburg said. "She was an advocate and supportive of a number of things that we were doing and she held our feet to the fire to make sure we were keeping our promises."

That a U.S. senator would work to advance the interests of a powerful home-state industry is not necessarily surprising.

She's obligated to support "job makers," said Larry Jacobs, a political scientist at the University of Minnesota. "Every presidential candidate is going to have issues that put them in sticky spots between the national political centers of the party and their constituents back home," he said.

"I think Sen. Klobuchar has been a very good representative of the state and a leader in Congress in being able to facilitate important conversations around medical devices," said Shaye Mandle, chief executive and president of the Medical Alley Association, which represents device makers and other health care businesses in Minnesota. "Most states don't have a medical device industry — every state has millions of patients that rely on medical technology."

THE POLITICS OF MEDICAL DEVICES

Medical devices provide clear benefits to millions of people, but a yearlong investigation by ICIJ, the AP and media partners in 36 countries has called into question whether the device industry has put patients in harm's way by rushing poorly tested products to market. Governments around the world, including the United States, hold even complex implants to a lower safety testing standard than most new drugs.

Many devices are implanted near vital organs or pressed against sensitive nerves. If they corrode or rupture, the results can be catastrophic. An entire generation of metal-on-metal artificial hips was discontinued after they were found to rot flesh and poison blood at high rates.

Minnesota is widely seen as the capital of the U.S. device industry. Medtronic, the world's largest medical device company, has its operational headquarters in Minneapolis. Klobuchar has developed relationships with the company's leadership — even inviting Medtronic's then-chief executive to be her guest at Obama's State of the Union address in 2011.

Hundreds of other device makers have offices in Minnesota and the industry employs nearly 30,000 people in the state. As a result, Democratic and Republican lawmakers from Minnesota have traditionally supported the industry's interests. Erik Paulsen, a Republican House member who was defeated in November, received more financial support from the device industry over the past 10 years than any other member of Congress.

Legislators from other states with device businesses have also gained reputations as friendly to the industry. Sen. Elizabeth Warren, a Massachusetts Democrat also running for president, has been criticized for omitting medical devices from her tough stance on the pharmaceutical industry. Sen. Bob Casey, a Democrat from Pennsylvania, is a leading recipient of device industry money and has fought for years to repeal a long-delayed 2.3 percent tax on medical devices intended to help fund the Affordable Care Act. Klobuchar has also fought to repeal the tax.

Over the past 10 years, Klobuchar's Senate campaigns have received more than $300,000 from the device industry, including corporations, unions, political action committees and individuals, according to the Center for Responsive Politics. Among Democrats, only Casey received more money from the device industry during the period.

In a statement, Medtronic said its dealings with government officials are consistent with its mission to alleviate pain, restore health and extend life.

"Medtronic has engaged with Senator Klobuchar on a range of policy issues over the years," Medtronic said in its statement. "She listens to our positions as one of her constituents, advocates for them when she agrees, and doesn't when she disagrees."

There have been times when Klobuchar has spoken out against the industry. In 2016, after the Minneapolis Star Tribune revealed that Medtronic failed to disclose more than 1,000 reports of "adverse events" relating to its Infuse Bone Graft device, Klobuchar wrote Medtronic asking why the company didn't report the information sooner.

She also criticized a program that allowed device makers to report some patient injuries and product problems years after the fact.

After the newspaper reported more details about Infuse device problems last year, Klobuchar and fellow Minnesota Sen. Tina Smith wrote Medtronic about the company's "failure to quickly and accurately report data to the FDA."

REGULATORY FIGHTS

In 2010, halfway through Klobuchar's first Senate term, the device industry became alarmed about a looming report that it feared would lead to heightened regulation — and a slower, and more expensive, path to get new products to market.

After a series of device safety scandals, the FDA had commissioned the Institute of Medicine, a nonpartisan group that advises federal authorities on health issues, to conduct an independent review of its fast-track device approval process.

The process allows companies to get approval for new devices based on "substantial equivalence" to previously approved products. It's how the vast majority of new medical devices are approved for the American public.

Already worried about a backlog in approvals, a prominent device trade group and its allies in Washington began pressing the FDA to ignore the Institute of Medicine's findings even before the institute finished its review. In a May 2010 letter, Klobuchar and Paulsen said they were concerned with the review and called for the FDA "to reject proposals that unduly burden small businesses and suppress the development of promising medical breakthroughs."

In July 2011, the Institute of Medicine concluded that the streamlined approval pathway was flawed and should be dismantled. The FDA quickly dismissed that recommendation.

Three months later, Klobuchar introduced legislation seeking to speed up medical device approvals by reducing the use of randomized and controlled clinical trials for some devices and limiting the amount of information medical device makers needed to provide to the FDA.

The consumer advocacy group Public Citizen denounced the bill, writing to Klobuchar that it would "weaken the already inadequate regulatory requirements for medical devices" and "would undoubtedly accelerate the rate of patient casualties."

The bill never left the Senate, but some key provisions that required the FDA to take a lighter approach with industry during device approvals and language that eased conflict of interest rules at the agency were ultimately included in the Senate's version of the landmark Food and Drug Administration Safety and Innovation Act, according to a press release from Klobuchar's office.

The senator characterized the changes as "common-sense reforms" that would give patients access to vital devices. Obama signed the legislation into law in 2012.

In 2016, Klobuchar introduced another bill aimed at easing device regulation. The Improving Medical Device Innovation Act would have required the FDA to explore alternatives for some device types to existing reporting requirements for patient injuries and device malfunctions "that will be least burdensome for device manufacturers." These reports are a primary way the FDA learns about dangerous devices once they are already on the market.

The bill also contained a provision to give device companies a voice in recommending which experts the FDA includes on panels reviewing their devices. "This is really noxious," said Dr. Peter Lurie, who held senior posts at the FDA from 2009 to 2017 and now heads the nonprofit watchdog group, the Center for Science in the Public Interest. "The last thing the agency needs is a bunch of self-interested input from sponsoring companies."

The Senate bill was never voted on but the provision regarding FDA expert panels lived on. In late 2016, Klobuchar joined an overwhelming majority of legislators to approve the 21st Century Cures Act. Signed into law by Obama, the measure seeks to accelerate product development for drugs and devices and strengthens the requirement that the FDA emphasize the "least burdensome means" for reviewing medical devices.

__

Woodman reported from New York. Sydney P. Freeberg of the International Consortium of Investigative Journalists reported from St. Petersburg, Florida.

You may also interested in

Delphi, Mobileye join forces on autonomous car platform

Aug 23, 2016

Auto parts and electronics company Delphi Automotive is joining with Israeli software maker Mobileye to develoDelphi and Mobileye plan to build a complete autonomous driving platformp the building blocks for a fully autonomous car in about two years

Beer mega merger: what court ruling means for troubled deal

Aug 23, 2016

A British court has recommended that two classes of shareholders be created and vote separately on AB InBev's 79 billion pound ($104 billion) takeover of SABMiller

How EpiPen's maker raised prices, and hackles, so much

Aug 23, 2016

Sky-high price hikes for an emergency allergy medicine are making drugmaker Mylan the latest target for patients and politicians infuriated by soaring drug costs

People also read these

US stocks take small losses as energy companies slide

Aug 19, 2016

US stocks take small losses as the dollar regains a bit of strength and energy companies trade lower

Officials: Zika won't hurt South Florida tourism in long run

Aug 20, 2016

The discovery of Zika-carrying mosquitoes in South Florida certainly isn't ideal for tourism, but local officials and business leaders are confident the long-term impact on the tourism industry will be minor

How EpiPen's maker raised prices, and hackles, so much

Aug 23, 2016

Sky-high price hikes for an emergency allergy medicine are making drugmaker Mylan the latest target for patients and politicians infuriated by soaring drug costs

Emporium Post fulfils the need to know all things about consumers and how businesses can take this opportunity to reach their own customers.

Contact us: sales@emporiumpost.com

Join our mailing list now!